Key facts
- This page summarizes Erin E. Burkhart's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Mar 2025, 19:53.
Erin E. Burkhart - 14 Mar 2025 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- GVP, Chief Accounting Officer
- Issuer ticker
- BMRN
- Reported as of
- 14 Mar 2025
- Net transaction value
- -$57,149
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2025, 19:53:01 UTC
- Prior SEC filing
- 25 Feb 2025
- Next SEC filing
- 20 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Erin E. Burkhart filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 18 Mar 2025.
Change
- Previous filing in this sequence was filed on 25 Feb 2025.
- Current net transaction value: -$57,149.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Tax liability
- Transaction value
- $57,149
- Shares
- -823
- Change %
- -6.3%
- Price
- $69.44
- Shares after
- 12,282
- Date
- 14 Mar 2025
- Ownership
- Direct
BMRN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,970
- Change %
- +49%
- Price
- $0.000000
- Shares after
- 18,252
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Award
- Transaction value
- $0
- Shares
- +9,230
- Change %
- Price
- $0.000000
- Shares after
- 9,230
- Date
- 17 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,230
- Exercise price
- $71.55
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units granted March 17, 2025. Price not applicable.
Footnote F2
Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter.